Scientists reprogram Patients' own cells to hunt blood cancer
NCT ID NCT03602612
Summary
This early-stage trial tests the safety of a new cell therapy for adults with multiple myeloma that hasn't responded to standard treatments. Doctors collect a patient's own immune cells, genetically modify them in a lab to better recognize cancer, and infuse them back after chemotherapy. The goal is to see if these modified cells can safely target and kill myeloma cells while monitoring for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.